相关实验视频

Updated: Sep 11, 2025

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

Published on: January 14, 2011

针对IL13RA2的新型免疫细胞因子表现出优越的抗瘤活性

Qing-Qing Jing¹, Jing Wen², Jian-Xia Ou¹

¹Biotherapeutics Discovery Research Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.

Acta pharmacologica Sinica

|August 13, 2025

概括

新型免疫细胞因子向介素-13受体α2 (IL13RA2) 显示出强大的抗瘤作用,副作用减少. 这些向疗法为IL13RA2阳性癌症提供了一个有希望的策略.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
分子生物学分子生物学

背景情况:

Th1类型的细胞因子,如联素-2 (IL-2) 和联素-12 (IL-12),具有抗瘤潜力,但受到毒性限制.
免疫细胞因子 (ICs),将细胞因子与抗体结合起来,在临床环境中证明了改善的治疗和安全性.

研究的目的:

研究IL13RA2在各种癌症中的表达和预后价值.
开发和评估用于癌症治疗的新型IL13RA2向免疫细胞因子.

主要方法:

使用TIMER2和TCGA数据集对IL13RA2表达的分析.
对IL13RA2产生一个中和抗体 (52B8),随后产生ICs (52B8-IL2,52B8-IL12,52B8-IL2/12).
在体外和体内评估IC在相关癌症模型中的疗效和安全性.

主要成果:

阐明了IL13RA2表达模式和预后意义.
开发的ICs在体外和体内表现出强大的,剂量依赖的抗癌活性.
ICs显示副作用减少,增强向传递,并增加免疫细胞透到瘤.

结论:

向IL13RA2的免疫细胞因子是有效和更安全的治疗剂.
这些IC代表了治疗IL13RA2阳性瘤的有希望的策略.
需要对这些新型免疫细胞因子进行进一步的临床研究.

关键词:

52B8 它们是什么?52B8-IL2/1212 这是一本书.在IL13RA2阳性瘤中.免疫细胞因子免疫细胞因子介质蛋白-12 介质蛋白-12 的作用.介质蛋白-2 介质蛋白-2 介质蛋白-2

更多相关视频

Isolation and Expansion of Cytotoxic Cytokine-induced Killer T Cells for Cancer Treatment

Isolation and Expansion of Cytotoxic Cytokine-induced Killer T Cells for Cancer Treatment

Published on: January 24, 2020

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles

Published on: June 28, 2021

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...